Beacon Therapeutics has raised over $75 million in a Series C financing led by Life Sciences at Goldman Sachs Alternatives.
Amount Raised
$75 Million
Round Type
Series C
Investors
Description
UK-based Beacon Therapeutics has raised over $75 million in an oversubscribed Series C financing. The funding will accelerate their commercial preparations for laru-zova and expand their pipeline for ocular diseases. The round saw participation from various prominent investors. This significant fundraising validates their strategy to tackle rare and prevalent ocular conditions.
Quick answer
Beacon Therapeutics raised $75 Million in a Series C round, dated January 8, 2026. Investors: Advent Life Sciences, Oxford Science Enterprises, Forbion, Syncona Limited, Retinal Degeneration Fund and Life Sciences At Goldman Sachs Alternatives.
- How much did Beacon Therapeutics raise?
- Beacon Therapeutics raised $75 Million in a Series C round on January 8, 2026.
- Who invested in Beacon Therapeutics?
- Advent Life Sciences, Oxford Science Enterprises, Forbion, Syncona Limited, Retinal Degeneration Fund and Life Sciences At Goldman Sachs Alternatives are named as investors in this round.
- What does Beacon Therapeutics do?
- Beacon Therapeutics is a clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases.
- Where is Beacon Therapeutics based and how big is it?
- Fundz records about 91 employees.
- Who are the decision-makers at Beacon Therapeutics?
- Fundz holds 1 contact at Beacon Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Beacon Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Altesa raised $75M (Series B) on February 19, 2026.
- Lario Therapeutics raised $2.4M (Grant) on February 19, 2026.
- Korsana Biosciences raised $175M (Series A) on February 18, 2026.
- Faeth Therapeutics raised $200M (Post-IPO Equity) on February 18, 2026.
- Sift Biosciences raised $3.7M (Pre-Seed) on February 18, 2026.
- Brainstorm Cell Therapeutics raised $1M (Post-IPO Equity) on February 13, 2026.
Who to call at Beacon Therapeutics, and when
A new round usually means Beacon Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Beacon Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Beacon Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Beacon Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Beacon Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Beacon Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.